RU2012112461A - Конъюгаты жирных кислот и ниацина и их применение - Google Patents

Конъюгаты жирных кислот и ниацина и их применение Download PDF

Info

Publication number
RU2012112461A
RU2012112461A RU2012112461/04A RU2012112461A RU2012112461A RU 2012112461 A RU2012112461 A RU 2012112461A RU 2012112461/04 A RU2012112461/04 A RU 2012112461/04A RU 2012112461 A RU2012112461 A RU 2012112461A RU 2012112461 A RU2012112461 A RU 2012112461A
Authority
RU
Russia
Prior art keywords
alkyl
compound according
independently
compound
6alkyl
Prior art date
Application number
RU2012112461/04A
Other languages
English (en)
Other versions
RU2569063C2 (ru
Inventor
Джилл К. МИЛН
Майкл Р. Джироусек
Джин Э. БЕМИС
Чи Б. Ву
Original Assignee
Катабэйсис Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625772&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2012112461(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Катабэйсис Фармасьютикалз, Инк. filed Critical Катабэйсис Фармасьютикалз, Инк.
Publication of RU2012112461A publication Critical patent/RU2012112461A/ru
Application granted granted Critical
Publication of RU2569063C2 publication Critical patent/RU2569063C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. Молекулярный конъюгат, содержащий ниацин и жирную кислоту, выбранную из омега-3 жирных кислот или жирных кислот, которые метаболизируются in vivo до омега-3 жирных кислот, где конъюгат содержит по меньшей мере один амид.2. Соединение Формулы Iили его фармацевтически приемлемая соль, гидрат, сольват, пролекарство, энантиомер или стереоизомер;где каждый из R, Rи Rнезависимо выбран из группы, состоящей из -Н, -D, -Cl, -F, -CN, -NH, -NH(C-Салкил), -N(C-Салкил), -NH(C(O)C-Cалкил), -N(C(O)C-Cалкил), -С(O)Н, -С(O)С-Салкила, -С(O)ОС-Салкила, -C(O)NH, -C(O)NH(C-Cалкил), -C(O)N(C-Cалкил), -C-Салкила, -O-C-Салкила, -S(O)С-Салкила и -S(O)С-Салкила;каждый из Wи Wнезависимо представляет собой ноль, О, S, NH, NR или Wи Wвместе могут образовывать имидазолидиновую или пиперазиновую группу при условии, что Wи Wне могут одновременно представлять собой О;каждый а, b, с и d независимо представляет собой -Н, -D, -СН, -ОСН, -ОСНСНили -C(O)OR, -O-Z или бензил или два из а, b, с и d, вместе с одинарным атомом углерода, к которому они присоединены, могут образовывать циклоалкил или гетероцикл;каждый n, о, р и q независимо равно 0 или 1;каждый L независимо представляет собой -O-, -S-, -S(O) -, -S(O)-, -S-S-,иликаждый g независимо равен 2, 3 или 4;каждый h независимо равен 1, 2, 3 или 4;каждый Rнезависимо представляет собой Н или C-Салкил или обе группы Rвместе с атомом азота, к которому они присоединены, могут образовывать гетероцикл;каждый Rнезависимо представляет собой е, В или неразветвленный или разветвленный C-Салкил, который может быть необязательно замещен ОН, NH, COR, CONH, фенилом, CHOH, имидазолом или аргинином;каждый е независимо представляет собой Н или любую из боковых цепей природных аминокислот;каждый Z независимо представляет собой -Н илиилипри усл

Claims (35)

1. Молекулярный конъюгат, содержащий ниацин и жирную кислоту, выбранную из омега-3 жирных кислот или жирных кислот, которые метаболизируются in vivo до омега-3 жирных кислот, где конъюгат содержит по меньшей мере один амид.
2. Соединение Формулы I
Figure 00000001
или его фармацевтически приемлемая соль, гидрат, сольват, пролекарство, энантиомер или стереоизомер;
где каждый из R1, R2 и R3 независимо выбран из группы, состоящей из -Н, -D, -Cl, -F, -CN, -NH2, -NH(C1-С3 алкил), -N(C1-С3 алкил)2, -NH(C(O)C1-C3 алкил), -N(C(O)C1-C3 алкил)2, -С(O)Н, -С(O)С1-С3 алкила, -С(O)ОС1-С3 алкила, -C(O)NH2, -C(O)NH(C1-C3 алкил), -C(O)N(C1-C3 алкил)2, -C1-С3 алкила, -O-C1-С3 алкила, -S(O)С1-С3 алкила и -S(O)2С1-С3 алкила;
каждый из W1 и W2 независимо представляет собой ноль, О, S, NH, NR или W1 и W2 вместе могут образовывать имидазолидиновую или пиперазиновую группу при условии, что W1 и W2 не могут одновременно представлять собой О;
каждый а, b, с и d независимо представляет собой -Н, -D, -СН3, -ОСН3, -ОСН2СН3 или -C(O)OR, -O-Z или бензил или два из а, b, с и d, вместе с одинарным атомом углерода, к которому они присоединены, могут образовывать циклоалкил или гетероцикл;
каждый n, о, р и q независимо равно 0 или 1;
каждый L независимо представляет собой -O-, -S-, -S(O) -, -S(O)2-, -S-S-,
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
или
Figure 00000020
каждый g независимо равен 2, 3 или 4;
каждый h независимо равен 1, 2, 3 или 4;
каждый R6 независимо представляет собой Н или C1-С6 алкил или обе группы R6 вместе с атомом азота, к которому они присоединены, могут образовывать гетероцикл;
каждый R7 независимо представляет собой е, В или неразветвленный или разветвленный C1-С10 алкил, который может быть необязательно замещен ОН, NH2, CO2R, CONH2, фенилом, C6H4OH, имидазолом или аргинином;
каждый е независимо представляет собой Н или любую из боковых цепей природных аминокислот;
каждый Z независимо представляет собой -Н или
Figure 00000021
или
Figure 00000022
при условии, что в соединении присутствует по меньшей мере один из
Figure 00000023
или
Figure 00000024
каждый r независимо равен 2, 3 или 7;
каждый s независимо равен 3, 5 или 6;
каждый t независимо равен 0 или 1;
каждый v независимо равен 1, 2 или 6;
каждый из R4 и R5 независимо представляет собой водород, дейтерий, -C1-C4 алкил, -галоген, -ОН, -С(O)С1-С4 алкил, -O-арил, -O-бензил, -OC(O)C1-C4 алкил, -C1-С3 алкен, -C1-С3 алкин, -С(O)С1-С4 алкил, -NH2, -NH(C1-C3 алкил), -N(C1-C3 алкил)2, -NH(С(O)С1-С3 алкил), -N(С(O)С1-С3 алкил)2, -SH, -S(C1-С3 алкил), -S(O)С1-С3 алкил, -S(O)2C1-C3 алкил; и
каждый R независимо представляет собой -Н или -С1-С3 алкил;
при условии, что
если каждый из m, n, о, p и q равен 0, каждый из W1 и W2 равен нулю и Z представляет собой
Figure 00000023
то t должен равняться 0; и
если каждый из m, n, о, p и q равен 0 и каждый из W1 и W2 равен нулю, то Z не может представлять собой
Figure 00000024
3. Соединение по п.2, отличающееся тем, что Z представляет собой
Figure 00000023
4. Соединение по п.3, отличающееся тем, что t равно 1.
5. Соединение по п.4, отличающееся тем, что r равно 2, и s равно 6.
6. Соединение по п.4, отличающееся тем, что r равно 3, и s равно 5.
7. Соединение по п.4, отличающееся тем, что r равно 7, и s равно 3.
8. Соединение по п.5, отличающееся тем, что L представляет собой -S-S-
9. Соединение по п.5, отличающееся тем, что L представляет собой -O-.
10. Соединение по п.5, отличающееся тем, что L представляет собой
Figure 00000020
11. Соединение по п.5, отличающееся тем, что L представляет собой
Figure 00000025
12. Соединение по п.5, отличающееся тем, что L представляет собой
Figure 00000007
Figure 00000009
или
Figure 00000011
13. Соединение по п.5, отличающееся тем, что L представляет собой
Figure 00000006
,
Figure 00000008
или
Figure 00000010
14. Соединение по п.5, отличающееся тем, что каждый из n, о, p и q равен 1.
15. Соединение по п.5, отличающееся тем, что два из n, о, p и q равны 1.
16. Соединение по п.5, отличающееся тем, что каждый из Wi и Wz представляет собой NH.
17. Соединение по п.5, отличающееся тем, что m равно 1, каждый из n, о, р и q равен 1 и L представляет собой О.
18. Соединение по п.5, отличающееся тем, что m равно 1, каждый из n, о, р и q равен 1 и L представляет собой -S-S-.
19. Соединение по п.5, отличающееся тем, что m равно 1, каждый из n и о равен 0, каждый из р и q равен 1 и L представляет собой
Figure 00000011
20. Соединение по п.5, отличающееся тем, что m равно 1, каждый из n, о, р и q равен 0 и L представляет собой
Figure 00000011
21. Соединение по п.5, отличающееся тем, что каждый из m, n и о равен 0 и каждый из р и q равен 1.
22. Соединение по п.5, отличающееся тем, что m равно 1, каждый из n и о равен 0, каждый из р и q равен 1 и L представляет собой
Figure 00000010
23. Соединение по п.5, отличающееся тем, что m равно 1, каждый из n и о равен 1, каждый из р и q равен 0 и L представляет собой
Figure 00000010
24. Соединение по п.5, отличающееся тем, что m равно 1, каждый из n, о, р и q равен 1 и L представляет собой
Figure 00000006
25. Соединение по п.5, отличающееся тем, что m равно 1, каждый из n, о, р и q равен 1 и L представляет собой NR6.
26. Соединение по п.5, отличающееся тем, что каждый из m, n и о равен 0 и каждый из р и q равен 1, а один из с представляет собой -СН3 и второй из с представляет собой -СН3.
27. Соединение по п.5, отличающееся тем, что m равно 1, каждый из n и о равен 1, каждый из р и q равен 0 и L представляет собой
Figure 00000020
28. Соединение по п.2, отличающееся тем, что соединение выбрано из группы, состоящей из N-(2-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-докоза-4,7,10,13,16,19-гексаенамидоэтокси)этил)никотинамида; N-(2-(2-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-докоза-4,7,10,13,16,19-гексаенамидоэтил)дисульфанил)этил)никотинамида; и N-(2-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-докоза-4,7,10,13,16,19-гексаенамидоэтиламино)этил)никотинамида.
29. Соединение по п.2, отличающееся тем, что соединение выбрано из группы, состоящей из 1,3-дигидроксипропан-2-ил-6-(4Z,7Z,10Z,13Z,16Z,19Z)-докоза-4,7,10,13,16,19-гексаенамидо-2-(никотинамидо)гексаноата; и 1,3-дигидроксипропан-2-ил-4-(4Z,7Z,10Z,13Z,16Z,19Z)-докоза-4,7,10,13,16,19-гексаенамидо-2-(никотинамидо)бутаноата.
30. Соединение по п.2, отличающееся тем, что соединение выбрано из группы, состоящей из N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-докоза-4,7,10,13,16,19-гексаенамидоэтил)никотинамида; N-(2-(5Z,8Z,11Z,14Z,17Z)-эйкоза-5,8,11,14,17-пентаенамидоэтил)никотинамида; и N-(1-(4Z,7Z,10Z,13Z,16Z,19Z)-докоза-4,7,10,13,16,19-гексаенамидо-2-метилпропан-2-ил)никотинамида.
31. Соединение по п.2, отличающееся тем, что соединение выбрано из группы, состоящей из (S)-6-((4Z,7Z,10Z,13Z,16Z,19Z)-докоза-4,7,10,13,16,19-гексаенамидо)-2-(никотинамидо)гексановой кислоты; (S)-2-((4Z,7Z,10Z,13Z,16Z,19Z)-докоза-4,7,10,13,16,19-гексаенамидо)-6-(никотинамидо)гексановой кислоты; (S)-6-((5Z,8Z,11Z,14Z,17Z)-эйкоза-5,8,11,14,17-пентаенамидо)-2-(никотинамидо)гексановой кислоты; (S)-2-((5Z,8Z,11Z,14Z,17Z)-эйкоза-5,8,11,14,17-пентаенамидо)-6-(никотинамидо)гексановой кислоты; и 2-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-докоза-4,7,10,13,16,19-гексаенамидоэтил)-4-(никотинамидо)бутановой кислоты.
32. Соединение по п.2, отличающееся тем, что соединение выбрано из группы, состоящей из (S)-((R)-1-(никотинамидо)пропан-2-ил)-2-((5Z,8Z,11Z,14Z,17Z)-эйкоза-5,8,11,14,17-пентаенамидо)пропаноата; и (S)-((R)-1-(никотинамид)пропан-2-ил)-2-((5Z,8Z,11Z,14Z,17Z)-эйкоза-5,8,11,14,17-пентаенамидо)-3-мэтилбутаноата.
33. Фармацевтическая композиция, содержащая соединение по п.2 и фармацевтически приемлемый носитель.
34. Способ лечения метаболического расстройства, включающий введение пациенту, который нуждается в таком лечении, эффективного количества соединения по п.2.
35. Способ по п.34, отличающийся тем, что метаболическое расстройство выбрано из гипертриглицеридемии, гиперхолестеринемии, жирового заболевания печенки, атеросклероза, заболевания коронарных сосудов сердца, диабета 2 типа, диабетической нефропатии, диабетической невропатии, диабетической ретинопатии, метаболического синдрома или сердечнососудистого заболевания.
RU2012112461/04A 2009-09-01 2010-08-31 Конъюгаты жирных кислот и ниацина и их применение RU2569063C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23890309P 2009-09-01 2009-09-01
US61/238,903 2009-09-01
US30852410P 2010-02-26 2010-02-26
US61/308,524 2010-02-26
US31095210P 2010-03-05 2010-03-05
US61/310,952 2010-03-05
PCT/US2010/047262 WO2011028689A1 (en) 2009-09-01 2010-08-31 Fatty acid niacin conjugates and their uses

Publications (2)

Publication Number Publication Date
RU2012112461A true RU2012112461A (ru) 2013-10-10
RU2569063C2 RU2569063C2 (ru) 2015-11-20

Family

ID=43625772

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012112461/04A RU2569063C2 (ru) 2009-09-01 2010-08-31 Конъюгаты жирных кислот и ниацина и их применение

Country Status (24)

Country Link
US (13) US8304551B2 (ru)
EP (1) EP2473045B1 (ru)
JP (1) JP5802209B2 (ru)
KR (1) KR101685734B1 (ru)
CN (1) CN102724877B (ru)
AR (1) AR078151A1 (ru)
AU (1) AU2010289683C1 (ru)
BR (1) BR112012004677A2 (ru)
CA (1) CA2772618C (ru)
CL (1) CL2010000935A1 (ru)
CR (1) CR20120167A (ru)
DK (1) DK2473045T3 (ru)
ES (1) ES2599626T3 (ru)
GT (1) GT201200056A (ru)
IL (1) IL218417A (ru)
IN (1) IN2012DN02661A (ru)
MX (1) MX2012002710A (ru)
MY (1) MY158504A (ru)
NI (1) NI201200038A (ru)
NZ (1) NZ599067A (ru)
RU (1) RU2569063C2 (ru)
SG (2) SG10201500431SA (ru)
TW (1) TWI519312B (ru)
WO (1) WO2011028689A1 (ru)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2733353T3 (es) 2007-11-09 2019-11-28 Basf As Compuestos lípidos para uso en productos cosméticos, como suplemento alimenticio o como un medicamento
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
CA2760877C (en) 2009-05-08 2020-09-08 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
CN102724877B (zh) 2009-09-01 2015-05-13 凯特贝希制药公司 脂肪酸烟酸缀合物及其用途
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
ES2618604T3 (es) 2010-11-05 2017-06-21 Pronova Biopharma Norge As Métodos de tratamiento usando compuestos lipídicos
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20140315786A1 (en) 2011-03-18 2014-10-23 Catabasis Pharmaceuticals, Inc. Use of intracellular enzymes for the release of covalently linked bioactives
EP2751071B1 (en) * 2011-08-31 2019-11-27 Jill C. Milne Fatty acid amides, compositions and methods of use
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
PL2800563T3 (pl) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc. Wzbogacone w DPA kompozycje wielonienasyconych kwasów tłuszczowych omega-3 w postaci wolnego kwasu
WO2013103958A1 (en) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
AU2013256362A1 (en) * 2012-05-01 2014-11-13 Catabasis Pharmaceuticals, Inc. Fatty acid conjugates of statin and FXR agonists: compositions and methods of use
JP6173437B2 (ja) 2012-05-07 2017-08-02 オムセラ・ファーマシューティカルズ・インコーポレイテッド スタチン及びω−３脂肪酸の組成物
CN107243078A (zh) * 2012-05-25 2017-10-13 克塔巴西斯制药有限公司 使前蛋白转化酶枯草溶菌素/kexin 9型（pcsk9）减少的方法
KR101520653B1 (ko) 2012-06-11 2015-05-15 주식회사 휴메딕스 복합 비타민 컨쥬게이트 및 그를 포함하는 항산화제
SG11201408769QA (en) 2012-06-29 2015-01-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
CN104780915A (zh) 2012-07-11 2015-07-15 埃尔舍利克斯治疗公司 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
WO2014068463A2 (en) * 2012-11-03 2014-05-08 Mahesh Kandula Compositions and methods for the treatment of inflammation and metabolic disorders
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
WO2014083476A2 (en) * 2012-11-27 2014-06-05 Mahesh Kandula Compositions and methods for the treatment of metabolic and lipid disorders
CN103007081B (zh) * 2012-11-27 2013-12-04 鞠法红 一种治疗非酒精性脂肪肝的中药组合物
WO2014087307A2 (en) * 2012-12-04 2014-06-12 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome and diabetes
CN103012419B (zh) * 2012-12-20 2015-01-07 中国科学院深圳先进技术研究院 一种罗丹明b衍生物的合成方法
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
WO2014106804A2 (en) * 2013-01-04 2014-07-10 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014106805A2 (en) * 2013-01-05 2014-07-10 Mahesh Kandula Fatty acid conjugates and their uses
WO2014107730A2 (en) * 2013-01-07 2014-07-10 Catabasis Pharmaceuticals, Inc. Use of fatty acid niacin conjugates for treating diseases
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
WO2014122575A2 (en) * 2013-02-08 2014-08-14 Mahesh Kandula Fatty acid conjugates for the treatment of inflammation and metabolic diseases
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
WO2014132134A1 (en) 2013-02-28 2014-09-04 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015073901A1 (en) * 2013-11-15 2015-05-21 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
MA41031A (fr) 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2016130417A1 (en) * 2015-02-11 2016-08-18 Omthera Pharmaceuticals Inc Omega-3 fatty acid prodrug compounds and uses thereof
AU2016256552B2 (en) 2015-04-28 2021-04-01 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018081167A1 (en) 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
EP3566055A4 (en) 2017-01-06 2020-12-02 Yumanity Therapeutics, Inc. TREATMENT METHODS FOR NEUROLOGICAL DISORDERS
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
CA3068254A1 (en) 2017-06-20 2018-12-27 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
KR20200096791A (ko) 2017-12-06 2020-08-13 바스프 에이에스 비알콜성 지방간염 치료용 지방산 유도체
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
CA3102404A1 (en) 2018-06-05 2019-12-12 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
KR102296068B1 (ko) 2018-09-24 2021-09-02 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
US11767314B2 (en) 2018-11-02 2023-09-26 Conopco, Inc. Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036951A (en) 1973-03-12 1977-07-19 Synergistics, Inc. Ultra-violet filtration with certain aminosalicylic acid esters
US4169923A (en) * 1974-10-15 1979-10-02 Paolo Ferruti High polymers containing nicotinic acid, process for their preparation and their use
CA1113486A (en) 1977-04-01 1981-12-01 Alfred Halpern Ultra-violet filtration with certain aminosalicylic acid esters
US4264517A (en) 1978-12-11 1981-04-28 G.D. Searle & Co. Alkylphenyl 5Z,8Z,11Z,14Z,17Z-eicosapentaenoates
US4619938A (en) * 1984-03-21 1986-10-28 Terumo Kabushiki Kaisha Fatty acid derivatives of aminoalkyl nicotinic acid esters and platelet aggregation inhibitors
IT1196348B (it) 1984-11-29 1988-11-16 Italfarmaco Spa Composti ad attivita'antiinfiammatoria
JPS61204171A (ja) 1985-03-06 1986-09-10 Terumo Corp ５−フルオロウラシル誘導体およびこれを含有する医薬製剤
JPH0248545B2 (ja) 1985-10-30 1990-10-25 Terumo Corp 33pirijinkarubonsann11okishidojudotaioyobikoreoganjusuruketsushobangyoshuyokuseizai
JPS62106080A (ja) 1985-11-01 1987-05-16 Terumo Corp エタノ−ルアミン誘導体およびこれを含有する抗高脂血症剤
JPS62106019A (ja) * 1985-11-01 1987-05-16 Terumo Corp 抗高脂血症剤
JPS62258362A (ja) * 1986-05-02 1987-11-10 Terumo Corp アミド誘導体およびこれを含有する５−リポキシゲナ−ゼ作用阻害剤
US4670465A (en) 1986-05-21 1987-06-02 Syntex (U.S.A.) Inc. Arachidonic acid analogs
JPH01121253A (ja) 1987-11-05 1989-05-12 Terumo Corp エタノールアミン誘導体包接化合物およびその製法
US5760261A (en) 1990-02-28 1998-06-02 Guttag; Alvin Higher fatty acid derivatives of salicylic acid and salts thereof
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
GB9508023D0 (en) 1995-04-20 1995-06-07 Scotia Holdings Plc Fatty acid derivatives
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
WO1996034858A1 (en) 1995-05-01 1996-11-07 Scotia Holdings Plc Nicotinic acid esters and pharmaceutical compositions containing them
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
GB9622636D0 (en) 1996-10-30 1997-01-08 Scotia Holdings Plc Presentation of bioactives
US5728732A (en) 1996-11-27 1998-03-17 Elizabeth Arden Company, Division Of Conopco, Inc. Skin treatment with salicylic acid esters and retinoids
NZ337698A (en) 1997-04-04 2001-07-27 Pfizer Prod Inc Nicotinamide derivatives for selective inhibition of phosphodiesterase type 4 (PDE4) and the production of tumour necrosis factor (TNF) useful for the treatment of respiratory, rheumatoid and allergic diseases
ATE329911T1 (de) 1998-08-07 2006-07-15 Applied Research Systems Fsh mimetika zur behandlung von infertilität
DE60021855T2 (de) * 1999-01-29 2006-05-18 Amersham Biosciences K.K. Temperatursensitives polymer und verfahren zu seiner herstellung
GB9930026D0 (en) 1999-12-21 2000-02-09 Univ Sheffield Novel compounds of unsaturated fatty acids
AU2700201A (en) 2000-01-31 2001-08-14 Pfizer Products Inc. Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
US6562995B1 (en) * 2000-12-21 2003-05-13 Beacon Laboratories, Inc. Delta dicarbonyl compounds and methods for using the same
KR20090028654A (ko) * 2001-01-19 2009-03-18 인스티튜트 오브 파마콜로지 앤드 톡시콜로지 아캐더미 오브 밀리터리 메디칼 사이언시스 피.엘.에이. 차이나 포타슘 채널의 기능을 조절하는 아민 유도체, 그의 제조방법 및 용도
IL156413A0 (en) * 2001-01-31 2004-01-04 Pfizer Prod Inc Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
EP1461014B1 (en) * 2001-12-04 2021-07-14 Ben Gurion University Of The Negev Research And Development Authority Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
US20040191278A1 (en) 2003-03-31 2004-09-30 Christensen Flemming Kjaergaar Topical agent for application to the skin prior to luminous treatment
RU2379292C2 (ru) * 2003-04-18 2010-01-20 Мемори Фармасьютиклз Корпорейшн Производные пиразола в качестве ингибиторов фосфодиэстеразы 4
US20050267091A1 (en) 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses
US20060105021A1 (en) * 2004-09-24 2006-05-18 Remington Direct Lp Cholesterol-reducing liquid
CN101102988B (zh) 2004-11-19 2011-12-14 马泰克生物科学公司 来自长链多不饱和脂肪酸的氧脂素及其制备和使用方法
US20090054423A1 (en) 2005-04-13 2009-02-26 Imbriglio Jason E Niacin receptor agonists, compositions containing such compounds and methods of treatment
ES2391305T3 (es) 2006-04-12 2012-11-23 Unilever N.V. Composición oral que comprende un ácido graso poliinsaturado y ácido salicílico para obtener un efecto antiinflamatorio en la piel
BRPI0913425A2 (pt) 2008-06-02 2015-11-24 Reddys Lab Ltd Dr formulações de niacina com liberação modificada
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
SG192488A1 (en) 2008-07-08 2013-08-30 Catabasis Pharmaceuticals Inc Fatty acid acetylated salicylates and their uses
WO2011006000A1 (en) 2009-07-08 2011-01-13 Haiyan Liu Berberine derivatives useful for modulating lipid levels and their methods of synthesis
CN102724877B (zh) 2009-09-01 2015-05-13 凯特贝希制药公司 脂肪酸烟酸缀合物及其用途
US9216224B2 (en) 2010-03-05 2015-12-22 Catabasis Pharmaceuticals, Inc. Fatty acid COX inhibitor derivatives and their uses
WO2011116312A1 (en) 2010-03-19 2011-09-22 Catabasis Pharmaceuticals, Inc. Fatty acid macrolide derivatives and their uses
US20140315786A1 (en) 2011-03-18 2014-10-23 Catabasis Pharmaceuticals, Inc. Use of intracellular enzymes for the release of covalently linked bioactives
US20120252810A1 (en) 2011-04-04 2012-10-04 Catabasis Pharmaceuticals, Inc. Fatty acid non-flushing niacin derivatives and their uses
AU2013256362A1 (en) 2012-05-01 2014-11-13 Catabasis Pharmaceuticals, Inc. Fatty acid conjugates of statin and FXR agonists: compositions and methods of use
CN107243078A (zh) 2012-05-25 2017-10-13 克塔巴西斯制药有限公司 使前蛋白转化酶枯草溶菌素/kexin 9型（pcsk9）减少的方法
WO2014107730A2 (en) 2013-01-07 2014-07-10 Catabasis Pharmaceuticals, Inc. Use of fatty acid niacin conjugates for treating diseases
WO2015073901A1 (en) 2013-11-15 2015-05-21 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates

Also Published As

Publication number Publication date
US8304552B2 (en) 2012-11-06
TW201117826A (en) 2011-06-01
US20120264791A1 (en) 2012-10-18
GT201200056A (es) 2015-02-11
EP2473045A1 (en) 2012-07-11
USRE45275E1 (en) 2014-12-02
ES2599626T3 (es) 2017-02-02
KR20120093183A (ko) 2012-08-22
USRE45261E1 (en) 2014-11-25
IL218417A (en) 2017-09-28
EP2473045B1 (en) 2016-08-17
US8940903B2 (en) 2015-01-27
SG10201500431SA (en) 2015-03-30
CA2772618A1 (en) 2011-03-10
CN102724877B (zh) 2015-05-13
US20120252850A1 (en) 2012-10-04
US8765964B2 (en) 2014-07-01
WO2011028689A1 (en) 2011-03-10
US20140228413A1 (en) 2014-08-14
US9278136B2 (en) 2016-03-08
CN102724877A (zh) 2012-10-10
CA2772618C (en) 2018-08-21
USRE46605E1 (en) 2017-11-14
US9486534B2 (en) 2016-11-08
JP2013503872A (ja) 2013-02-04
NI201200038A (es) 2012-08-17
IN2012DN02661A (ru) 2015-09-11
IL218417A0 (en) 2012-04-30
US8765963B2 (en) 2014-07-01
DK2473045T3 (en) 2016-12-12
US9238077B2 (en) 2016-01-19
CL2010000935A1 (es) 2011-04-15
BR112012004677A2 (pt) 2020-11-03
US20160346397A1 (en) 2016-12-01
AU2010289683C1 (en) 2014-10-16
US20120184585A1 (en) 2012-07-19
SG178948A1 (en) 2012-04-27
US20150209439A1 (en) 2015-07-30
AU2010289683B2 (en) 2014-06-12
KR101685734B1 (ko) 2016-12-12
JP5802209B2 (ja) 2015-10-28
CR20120167A (es) 2012-08-21
US8304551B2 (en) 2012-11-06
AU2010289683A1 (en) 2012-04-19
RU2569063C2 (ru) 2015-11-20
EP2473045A4 (en) 2013-11-20
MY158504A (en) 2016-10-14
US20180028674A1 (en) 2018-02-01
US20140113940A1 (en) 2014-04-24
US20140249189A1 (en) 2014-09-04
US20110053990A1 (en) 2011-03-03
NZ599067A (en) 2014-04-30
AR078151A1 (es) 2011-10-19
MX2012002710A (es) 2012-04-19
TWI519312B (zh) 2016-02-01

Similar Documents

Publication Publication Date Title
RU2012112461A (ru) Конъюгаты жирных кислот и ниацина и их применение
RU2017121906A (ru) Конъюгаты цистеамина и жирной кислоты и их применение в качестве активаторов аутофагии
WO2011089529A4 (en) Salicylate fatty acid derivatives
RU2009106934A (ru) Производное аминофосфата и модулятор рецептора s1p, содержащий его в качестве активного ингредиента
JP2010509375A5 (ru)
NZ580973A (en) Pharmaceutical formulations containing lipoic acid derivatives
JP2011520815A5 (ru)
CA2443950A1 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
HUP0204515A2 (hu) 4-Aminopiperidin-származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
JP2012526094A5 (ru)
RU2001113733A (ru) N-(2-арилпропионил) сульфонамиды и содержащие их фармацевтические препараты
RU2009145541A (ru) Терапевтические соединения
JP2006520808A5 (ru)
RU2014145819A (ru) Бициклическое соединение
JP2023523953A (ja) 脳腫瘍における改善された血液脳関門浸透性及び滞留性を備えた、スケーラブルなチロインテグリンアンタゴニストの組成物
RU2008110644A (ru) Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
RU2013136861A (ru) Новое производное индола или индазола или его соль
JP2011518816A5 (ru)
US20110082202A1 (en) Fatty acid acifran derivatives and their uses
US8680151B2 (en) Compounds, compositions and methods for treating or preventing hypoxic or ischemic injury
JP2005504795A5 (ru)
KR890006228A (ko) 항종양제로서 폴리아민 유도체
YU58601A (sh) Derivati fenilalaninola
WO2011044136A1 (en) Fatty acid acipimox derivatives and their uses
JP2008519001A5 (ru)